MultiCell Technologies, Inc. (MCET)の価格はいくらですか

MultiCell Technologies, Inc. (MCET)の価格は$0.00001です

MultiCell Technologies, Inc. (MCET)の時価総額は何ですか

MultiCell Technologies, Inc. (MCET)の時価総額は$50.01Kです

MultiCell Technologies, Inc.（MCET）営業利益率

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

年	営業利益率	変化
2026 (TTM)	-1,465.60%	0.00%
2014	-1,465.60%	-47.16%
2013	-2,773.89%	0.00%

年

営業利益率

変化

2026 (TTM)

-1,465.60%

0.00%

2014

-1,465.60%

-47.16%

2013

-2,773.89%

0.00%

企業	営業利益率	営業利益率の差	国
Novo Nordisk A/S NVO.US	41.30%	-100.03%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	35.45%	-100.02%	US
Regeneron Pharmaceuticals, Inc. REGN.US	24.95%	-100.02%	US
UCB SA UCB.BR	25.32%	-100.02%	BE
CSL Limited CSL.AX	25.72%	-100.02%	AU

企業

営業利益率

営業利益率の差

国